DK0774974T3 - Nucleinsyrevaccine - Google Patents

Nucleinsyrevaccine

Info

Publication number
DK0774974T3
DK0774974T3 DK95929336T DK95929336T DK0774974T3 DK 0774974 T3 DK0774974 T3 DK 0774974T3 DK 95929336 T DK95929336 T DK 95929336T DK 95929336 T DK95929336 T DK 95929336T DK 0774974 T3 DK0774974 T3 DK 0774974T3
Authority
DK
Denmark
Prior art keywords
block copolymers
nucleic acid
acid vaccine
useful
molecular weight
Prior art date
Application number
DK95929336T
Other languages
Danish (da)
English (en)
Inventor
Mannarsamy Balasubramanian
Mark Joseph Newman
R Martin Emanuele
Carlos A Rivera-Marrero
Charles W Todd
Robert Newton Brey Iii
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Application granted granted Critical
Publication of DK0774974T3 publication Critical patent/DK0774974T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2642—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds characterised by the catalyst used
    • C08G65/2645—Metals or compounds thereof, e.g. salts
    • C08G65/2648—Alkali metals or compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2642—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds characterised by the catalyst used
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
DK95929336T 1994-08-09 1995-08-09 Nucleinsyrevaccine DK0774974T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29281494A 1994-08-09 1994-08-09
PCT/US1995/009638 WO1996004932A1 (en) 1994-08-09 1995-08-09 Novel vaccine adjuvant and vaccine

Publications (1)

Publication Number Publication Date
DK0774974T3 true DK0774974T3 (da) 2002-06-17

Family

ID=23126314

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95929336T DK0774974T3 (da) 1994-08-09 1995-08-09 Nucleinsyrevaccine

Country Status (11)

Country Link
US (5) US6086899A (es)
EP (2) EP1181937A3 (es)
JP (1) JP2002502434A (es)
AT (1) ATE218066T1 (es)
AU (1) AU3272495A (es)
CA (1) CA2196801C (es)
DE (1) DE69526856T2 (es)
DK (1) DK0774974T3 (es)
ES (1) ES2180651T3 (es)
HK (1) HK1044890A1 (es)
WO (1) WO1996004932A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
FR2759298B1 (fr) * 1997-02-10 1999-04-09 Rhone Poulenc Rorer Sa Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
AU5345999A (en) * 1998-08-14 2000-03-06 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
JP2003522133A (ja) * 1999-12-28 2003-07-22 ノバルティス アクチエンゲゼルシャフト 持続性導入遺伝子発現を実現する方法
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
CA2407074A1 (en) * 2000-04-21 2001-11-01 Jukka Hartikka Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1315672A4 (en) * 2000-06-22 2006-04-26 Rxkinetix Inc ADMINISTRATIVE COMPOSITION COMPOSITION AND METHOD FOR THE ADMINISTRATION OF ANTIGENES AND OTHER ACTIVE SUBSTANCES
EP1335953A4 (en) * 2000-06-23 2005-03-30 Merck & Co Inc POLYNUCLEOTIDE VACCINE ADJUVANTS AND FORMULATIONS CONTAINING CATIONIC SURFACTANTS, METHODS OF USE THEREOF
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
JP4202928B2 (ja) 2002-01-17 2008-12-24 アルファ ラバル コーポレート アクティエボラーグ 一体式熱交換器を有する浸水式蒸発器
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
CA2508281C (en) 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US7521187B2 (en) 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EP2153848A3 (en) * 2005-01-27 2010-07-21 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins
WO2006105993A2 (en) 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
CA2678963C (en) * 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8598321B2 (en) * 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
DK2224951T3 (da) * 2007-12-21 2020-01-06 Zoetis Services Llc Varmebehandlede bakteriner og emulsionsvacciner, der er fremstillet af sådanne varmebehandlede bakteriner
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2010072769A1 (de) 2008-12-23 2010-07-01 Basf Se Verfahren zur herstellung von polyether-blockcopolymeren
US9545421B2 (en) 2010-05-04 2017-01-17 General Electric Company Nucleic acid delivery vehicle and uses thereof
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP4151738A1 (en) * 2012-02-29 2023-03-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retroviral transduction using poloxamers
EP3166617B1 (en) 2014-07-07 2024-01-10 LifeRaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
CN106947074B (zh) * 2017-03-13 2019-05-24 浙江皇马表面活性剂研究有限公司 一种低不饱和度高活性高分子量聚醚多元醇的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3393243A (en) * 1964-09-24 1968-07-16 Jefferson Chem Co Inc Process of preparing polyoxypropylene polyether polyols
US4118067A (en) * 1976-12-13 1978-10-03 American Safety Equipment Corporation Inertia-responsive vehicle seat back latch mechanism
US4103967A (en) * 1976-12-13 1978-08-01 American Safety Equipment Corporation Roller seat back latch mechanism
US4318569A (en) * 1977-07-28 1982-03-09 Ford Motor Company Seat back latch mechanism
US4365837A (en) * 1981-03-05 1982-12-28 Hoover Universal, Inc. Inertial lock
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
CA1312399C (en) * 1986-11-21 1993-01-05 Jay Gregory Otten Process for preparing capped polyoxyalkylene block polyethers
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5567859A (en) 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE3855974T2 (de) * 1987-02-26 1997-12-04 Arco Chem Tech Herstellung eines filtrierbaren, für die Alkylenoxidpolymerisation verwendbaren Doppelmetallcyanidkomplex-Katalysators
GB8912456D0 (en) * 1989-05-31 1989-07-19 Secr Defence Polymerisation of cyclic ether monomers capable of undergoing cationic oxonium ion ring-opening polymerisation
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
KR100224539B1 (ko) * 1991-03-19 1999-10-15 잭 제이 루체스 개선된 생물학적 활성을 가진 폴리옥시프로필렌/폴리옥시에틸렌 공중합체 조성물
JP3819422B2 (ja) * 1993-10-15 2006-09-06 シトリックス コーポレイション 治療用送達組成物及びその使用方法
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5722730A (en) * 1996-10-29 1998-03-03 Excel Industries, Inc. Reinforcement member for pivotable assembly
US6209955B1 (en) * 1998-10-21 2001-04-03 Johnson Controls Technology Company Vehicle seat with a yielding recliner stop

Also Published As

Publication number Publication date
WO1996004932A1 (en) 1996-02-22
US6149922A (en) 2000-11-21
ES2180651T3 (es) 2003-02-16
EP0774974A1 (en) 1997-05-28
EP1181937A2 (en) 2002-02-27
JP2002502434A (ja) 2002-01-22
HK1044890A1 (zh) 2002-11-08
US7045576B2 (en) 2006-05-16
DE69526856D1 (de) 2002-07-04
US20020197599A1 (en) 2002-12-26
CA2196801C (en) 2008-07-22
AU3272495A (en) 1996-03-07
US6086899A (en) 2000-07-11
EP0774974B1 (en) 2002-05-29
DE69526856T2 (de) 2003-01-16
CA2196801A1 (en) 1996-02-22
US6844001B2 (en) 2005-01-18
ATE218066T1 (de) 2002-06-15
US20050070670A1 (en) 2005-03-31
EP1181937A3 (en) 2004-02-04
US6416947B1 (en) 2002-07-09

Similar Documents

Publication Publication Date Title
DK0774974T3 (da) Nucleinsyrevaccine
CY1117235T1 (el) Νεϊσσεριακες συνθεσεις συνδυασμου
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
ATE328890T1 (de) Immunomodulatorische oligonukleotide
DE69731285D1 (de) Langwellig fluorezierende proteine
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DE69725825D1 (de) 5-HT1F-Agonisten
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
SE9904377D0 (sv) Pharmaceutical combinations
DK0821693T3 (da) Nye DNA-sekvenser fra human cytomegalovirus (HCMV)
ATE377428T1 (de) Rotavirus-impfstoff
NO20073914L (no) Biologisk aktive peptider
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE69421665T2 (de) Anomere Fluorribosylamine
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose